The Association of VA Hematology/Oncology (AVAHO) is a non-profit organization dedicated to improving the lives of Veterans diagnosed with cancer and hematologic disorders. AVAHO’s current membership of nearly 1000 healthcare professionals is comprised of medical, surgical, and radiation oncologists, hematologists, pharmacists, mid-level providers, cancer registrars, social workers, and allied healthcare professionals from across the country. To advocate for quality comprehensive cancer care for Veterans, AVAHO supports and provides educational activities, networking opportunities and facilitates improved research capabilities for hematology/oncology professionals within the VA healthcare system. AVAHO looks forward to expanding its member base, creating an environment for continuous support and development for both Veterans and the providers who deliver their outstanding care.
Julie Lawson, M.A.
Executive Director, Association of VA Hematology/Oncology (AVAHO)
Please click the button below:
Julie Lawson, M.A.
Executive Director, Association of VA Hematology/Oncology (AVAHO)
This program will discuss the nuances of EGFR-mutated non-small-cell lung cancer and the impact of genomic and metabolic pathways for treatment selection.
This activity will explore the management of patients with of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, and relapsed/refractory, and secondary AML. A summary of approaches to TRAE recognition and mitigation will also be discussed.
Friday, July 14, 2023
12:00PM – 1:00PM ET
Please note this virtual program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
This activity will explore the management of patients with of treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This program will address approaches to individualize selection of therapy and the role of minimal residual disease (MRD) in monitoring treatment effectiveness. A summary of approaches to TRAE recognition and mitigation will also be addressed.
This activity will explore emerging treatment options and novel management strategies of patients with relapsed/refractory MCL or CLL/SLL.
This enduring program focuses on providing Veterans Affairs clinicians with updates in the management of advanced melanoma, including consideration of anti-LAG-3 antibodies. It also provides an overview of the latest trials considering anti-LAG-3 antibodies for the management of advanced melanoma, and updates on immunotherapy approaches in clinical practice.
RELEASED DATE: April 25, 2023
EXPIRATION DATE: April 25, 2024
Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.
Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.
Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.
